Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Update

Dermata Therapeutics, Inc. (NASDAQ:DRMA) saw a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 294,200 shares, a growth of 112.9% from the January 15th total of 138,200 shares. Based on an average daily trading volume, of 460,200 shares, the days-to-cover ratio is presently 0.6 days. Approximately 47.5% of the shares of the company are short sold.

Dermata Therapeutics Trading Up 5.3 %

DRMA stock opened at $1.19 on Friday. Dermata Therapeutics has a 1 year low of $1.00 and a 1 year high of $7.62. The stock’s fifty day moving average is $1.25 and its two-hundred day moving average is $1.48.

Dermata Therapeutics Company Profile

Dermata Therapeutics, Inc, a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.